Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01873248 · ClinicalTrials.gov registry record · Early Phase 1
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
A Early Phase 1 study of Neuroendocrine Tumors, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT01873248: Completed Early Phase 1 study of Neuroendocrine Tumors, sponsored by Jonsson Comprehensive Cancer Center.
NCT01873248 is a Early Phase 1 study of Neuroendocrine Tumors that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 100 participants, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01873248, a Early Phase 1 study of Neuroendocrine Tumors, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors. The objective of this study was to determine referring physicians' perspectives on the impact of DOTATATE on the management of neuroendocrine tumors.
Primary Outcome
The study will collect questionnaire data from referring physicians on intended patient management before and after PET/CT.
Conditions Studied
Interventions
- DRUG 68Ga-DOTATATE
Study Locations (1)
California
- University of California Los Angeles, Nuclear Medicine Clinic of the Department of Molecular and Medical Pharmacology - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2013-08-26 |
| Est. Completion | 2017-06-16 |
| Phase | Early Phase 1 |
What the finished NCT01873248 record still lists
NCT01873248 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which 68Ga-DOTATATE is the first listed.
NCT01873248 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01873248 about?
NCT01873248 is a clinical study titled "Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective". Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors. The objective of this study was to determine referring physicians' perspectives on the impact of DOTATATE on the management of neuroendocrine tumors.
What is the current status of trial NCT01873248?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2013-08-26. Estimated completion is 2017-06-16.
What conditions does trial NCT01873248 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors.
What interventions are being tested in trial NCT01873248?
The interventions under investigation include: 68Ga-DOTATATE (DRUG).
Who is sponsoring clinical trial NCT01873248?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01873248 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01873248's enrollment target sits among peer trials
100 22nd of 52 higher than 31 of 52 other Neuroendocrine Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
ACTIVE NOT RECRUITING · Early Phase 1
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI